BRISBANE, Calif. - VaxGen announced today that it has submitted a proposal to the U.S. Department of Health and Human Services (HHS) describing its plan to provide up to 75 million doses of its recombinant anthrax vaccine to the U.S. strategic
national stockpile of biodefense products. The HHS has indicated that it intends to award purchase contracts for such a vaccine on or about Aug. 9, 2004.
VaxGen has already received two contracts from the National Institute of
Allergy and Infectious Diseases (NIAID) to develop its recombinant anthrax
vaccine candidate. The contracts are valued at more than $100 million. The
company is also developing an attenuated smallpox vaccine in partnership with
the Chemo-Sero Research Institute (Kaketsuken) of Kumamoto, Japan.
Additionally, VaxGen announced that it has discontinued early-stage
development of a recombinant plague vaccine after the NIAID elected not to
provide research and development funding for this vaccine. The company's
decision will have no effect on the development of its other product
VaxGen, Inc. is a biopharmaceutical company engaged in the development,
manufacture and commercialization of biologic products for the prevention and
treatment of human infectious diseases. The company is developing preventive vaccines against anthrax and smallpox, and an anthrax monoclonal antibody in collaboration with Avanir Pharmaceuticals.
Source: VaxGen, Inc.